Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Masitinib versus placebo in progressive multiple sclerosis without relapse
2021-000639-30Phase 3Active
- Sponsor
- AB Science
- Start
- Sep 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in primary progressive multiple sclerosis (PPMS) and secondary-progressive multiple sclerosis (SPMS) comparing Masitinib dose-titration arm with Placebo arm (2 arms). Primary endpoint: Time to 12-week confirmed disability progression on EDSS. Started Sep 2021; status: active.
02
Drugs
masitinib
03
Conditions
primary progressive multiple sclerosis (PPMS)secondary-progressive multiple sclerosis (SPMS)
Beyond the preview
Go deeper on 2021-000639-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-000639-30.